EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer

Michael Rose1 · Angela Maurer1 · Julia Wirtz5 · Andreas Bleilevens2 · Tanja Waldmann2 · Maximilian Wenz1 · Marie Eyll1 · Mirja Geelvink1 · Melanie Geretzig1 · Nadine Rüehl1 · Bernd Denecke3 · Elke Eltze4 · Edwin Herrmann5 · Marieta Toma6,12 · David Horst7 · Tobias Grimm8 · Stefan Denzinger9 · Thorsten Ecke10 · Thomas Alexander Vögeli11 · Ruth Knuechel1 · Jochen Maurer2 · Nadine T. Gaisa1

Received: 16 March 2020 / Revised: 11 August 2020 / Accepted: 10 September 2020 / Published online: 25 September 2020
© The Author(s) 2020. This article is published with open access

Abstract
Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively characterized pure and mixed Sq-BLCA (n = 125) on genetic and protein expression level, and performed functional pathway and drug-response analyses with cell line models and isolated primary SCC (p-SCC) cells of the human urinary bladder. We identified abundant EGFR expression in 95% of Sq-BLCA without evidence for activating EGFR mutations. Both SCaBER and p-SCC cells were sensitive to EGFR tyrosine kinase inhibitors (TKIs: erlotinib and gefitinib). Combined treatment with anti-EGFR TKIs and varying chemotherapeutics led to a concentration-dependent synergism in SCC cells according to the Chou-Talalay method. In addition, the siRNA knockdown of EGFR impaired SCaBER viability suggesting a putative “Achilles heel” of Sq-BLCA. The observed effects seem Sq-BLCA-specific since non-basal urothelial cancer cells were characterized by poor TKI sensitivity associated with a short-term feedback response potentially attenuating anti-tumor activity. Hence, our findings give further insights into a crucial, Sq-BLCA-specific role of the ERBB signaling pathway proposing improved effectiveness of anti-EGFR based regimens in combination with chemotherapeutics in squamous bladder cancers with wild-type EGFR-overexpression.

Introduction
Bladder cancer is the 9th common cancer worldwide [1] comprising a wide spectrum of tumors including cancers with squamous differentiation (Sq-BLCA), i.e., urothelial cancers with substantial squamous-differentiation...
with standard chemotherapy. 

provide evidence that the viability of SCC-derived cells squamous bladder cancer. Our functional in vitro of EGFR TKI treatment speci
to demonstrate superior treatment ef

assessing EGFR inhibitors in patients with MIBC failed subtypes [20]. Importantly, unselected clinical studies cohorts and different histopathological and molecular 

overexpression varied strongly between 27 to 74%

studies of EGFR expression in bladder cancer EGFR 
tions (e.g., non-small cell lung cancer (NSCLC)) [16]. In 

EGFR (e.g., head and neck squamous cell carcinoma 

basal cancers, whereas non-basal BLCA showed increased mRNA expression of different ERBBs.

Next, EGFR and ERBB2/HER2 protein expression was evaluated in a large cohort of bladder cancers with sub-
stantial squamous differentiation comprising MIX-SCC (n = 50) and pure SCC (n = 75) (Table 1). Urothelial BLCA (MIBC, n = 63) without squamous differentiation served as reference (Supplementary Table 1). In 95% (110/116) of Sq-BLCA EGFR protein was expressed (Fig. 1b and c). 61% of these tumors (71/116) showed EGFR overexpression (score 3) (mean score: 2.41 ± 0.87; 95% CI: 2.26–2.57) (Fig. 1c), whereas 21% of MIBC exhibited comparable values (mean score: 1.51 ± 1.07; 95% CI: 1.23–1.78) (Fig. 1d). Conversely, 4% (5/117) of Sq-BLCA expressed ERBB2/HER2 (HER2 DAKO score of 2 or 3) (mean score: 0.17 ± 0.51; 95% CI: 0.08–0.27) (Fig. 1e), whereas 60% of MIBC showed ERBB2/HER2 protein expression (mean score: 1.57 ± 0.90; 95% CI: 1.33–1.81) (Fig. 1f). There was no difference between MIX-SCC and SCC.

In parallel, genetic EGFR alterations were studied, i.e., EGFR amplification, EGFR activating mutations, and activating RAS mutations (HRAS, KRAS, NRAS) which would convey resistance to EGFR inhibitor treatment. No activating mutations in the EGFR gene (0/71) and only a single activating RAS mutation (1/69; HRAS p.Q61L) was identified (Fig. 1g and Supplementary Table 2). EGFR and ERBB2 copy number analysis by FISH revealed an amplification of the EGFR gene in 8% (9/115) and of ERBB2 in 0% (0/105). EGFR cluster amplifications overlapped with strong EGFR protein expression (7/9) (Supplementary Table 3).

Efficacy of EGFR TKI and chemotherapeutical treatment on urothelial and SCC-derived cancer cells

First-generation tyrosine kinase inhibitors (TKIs), erlotinib, and gefitinib are known to target wild-type EGFR by
competing reversibly with adenosine triphosphate (ATP) at the kinase domain [23]. Single drug sensitivity assays were performed (Fig. 2a–d) on SCaBER cells and urothelial cancer cell lines (HT1376, RT112, J82) to calculate relative IC\textsubscript{50} values for each cell line and drug (Fig. 2e–h). The oropharyngeal cancer cell lines FaDu and UT-SCC 09 served as control groups for pure squamous cancer cells. Expression of ERBB genes (Supplementary Fig. 1) and the status of EGFR amplification, EGFR or RAS activating mutations for used cell lines have been assessed (Supplementary Table 4).

SCaBER was by far the most sensitive cell line tested (erlotinib: IC\textsubscript{50} = 0.27 µM, gefitinib: IC\textsubscript{50} = 0.35 µM). FaDu and UT-SCC 09 exhibited high to intermediate sensitivity to both inhibitors (FaDu: erlotinib-IC\textsubscript{50} = 1.07 µM, gefitinib-IC\textsubscript{50} = 2.01 µM; UT-SCC 09: erlotinib-IC\textsubscript{50} = 0.49 µM,
Gefitinib-IC\textsubscript{50} = 0.80 µM). The basal bladder cancer cell line HT1376 showed intermediate sensitivity to erlotinib (erlotinib-IC\textsubscript{50} = 2.23 µM) but not to gefitinib treatment (gefitinib-IC\textsubscript{50} = 6.68 µM). RT112 and J82 cells were poorly sensitive (erlotinib-IC\textsubscript{50} > 3 µM; gefitinib-IC\textsubscript{50} > 7 µM) to both inhibitors. In parallel, we determined the response to gemcitabine and cisplatin as known standard chemotherapeutics for bladder cancer. ScaBER cells were less sensitive to cisplatin (IC\textsubscript{50} = 10.71 µM) or gemcitabine (IC\textsubscript{50} = 0.58 µM) compared to all other cell lines.

**ERBB signaling in response to EGF stimulation, EGFR inhibition, and siRNA-mediated EGFR knockdown in urothelial- and Sq-BLCA cells**

ScaBER, J82, and HT1376 cells were treated with EGF (10 ng/ml), erlotinib (determined IC\textsubscript{50} for each cell line) or combined for 24 h (Fig. 3a). For detailed densitometric evaluation see Supplementary Figs. 2–4. Under basal conditions in ScaBER, 47% of total EGFR protein showed phosphorylation that was associated with 82% activation of the downstream kinase ERK. Upon erlotinib treatment the signaling cascade downstream of EGFR was abrogated by Δp-ERK: 31.8% (Δp-ERK) and Δp-AKT: 29.8% (Δp-AKT). EGF stimulation fostered signaling, i.e. p-EGFR protein up to 125%, p-ERK and p-AKT up to 89.5% and 106%, respectively, while their activation was blocked by 45.8% (Δp-EGFR Tyr1068), 38.2% (Δp-EGFR Tyr1045), 23.1% (Δp-ERK) and 15.9% (Δp-AKT) due to simultaneous erlotinib treatment. ERK activation was also diminished by erlotinib in HT1376 bladder cancer cells (Supplementary Fig. 4), in particular, reduced by erlotinib under stimulatory conditions (Δp-ERK: 51.7%). In urothelial J82 cells only a slight inhibitory effect was observed upon treatment with both erlotinib alone and in combination with EGF (Δp-ERK 8% and 22.6%) while AKT showed even increased phosphorylation (Δp-AKT 17.7% and 8.5%).

A feedback mechanism potentially regulating ERBB receptor and ligand expression was studied (Fig. 3b–i). Twenty-four hours after EGF and/or erlotinib treatment mRNA expression of both ERBB receptors (EGFR, ERBB2, ERBB3, and ERBB4) and ERBB ligands (amphiregulin (AREG), epiregulin (EREG), and heparin-binding EGF like growth factor (HB-EGF)) [24] was determined. In addition, the transcriptional regulator SRY-related high-mobility group box 9 (Sox9) (Fig. 3b–i) was selected as known target gene of the EGFR-ERK axis [25]. Compared to the DMSO control, erlotinib treatment caused a slight upregulation of ERBB2 (fold change (FC): 2.1) and ERBB3 (FC: 1.9) mRNA expression, however, re-expression was shown for
**ERBB4** mRNA in SCaBER (FC: 20.7) (Fig. 3e) and HT1376 cells (FC: 3.4) (Supplementary Fig. 4). EGFR inhibition by erlotinib further reduced SOX9 (FC: 0.16) and HB-EGF expression (FC: 0.55) while mRNA levels of the low-affinity ligands AREG and EREG were not significantly altered in SCaBER cells. EGF stimulation resulted in an upregulation of AREG and EREG. As EGF stimulation counteracts the impact of erlotinib upon combined treatment a complete inhibition of the EGFR signaling cascade was not expected (see Fig. 3a) and expression of receptors or ligands were consequently not substantially altered compared to DMSO controls. Interestingly, in non-basal and TKI resistant cancer cells (J82), inhibition of EGFR phosphorylation mediated by erlotinib was associated with increased mRNA expression of EGFR (FC: 44.6), ERBB3 (FC: 92.3) and EREG (FC: 3.5). Upregulation of EGFR and ERBB3 was still present upon EGF stimulation in combination with erlotinib (Fig. 3b and d) suggesting a feedback loop with potentially compensatory effects as the target gene SOX9 was not downregulated by applied TKIs (FC: 1.6) (Fig. 3i).

The knockdown of EGFR by siRNA led to impaired cell viability 48 h after siRNA transfection in SCaBER cells (Fig. 4a–c). The number of living cells at different time points after siRNA transfection was reduced by up to 43.3% (Fig. 4c). Basal apoptosis was not affected by EGFR knockdown (data not shown). No impact on cell viability was observed in urothelial J82 cancer cells over 96 h (Supplementary Fig. 5). Expression analyses of ERBB receptors revealed an EGFR-knockdown associated upregulation of ERBB2 and ERBB4 in SCaBER (Fig. 4d) while J82 cancer cells did not show upregulation of ERBB expression at all (Supplementary Fig. 5).

**Combined application of anti-EGFR TKIs and chemotherapeutics enhances drug efficacy in vitro**

Next, drug-response assays with combinations of erlotinib, gefitinib, and two routinely used chemotherapeutics were performed for SCaBER and FaDu cells (Fig. 5a–d). A combined drug effect was determined by calculating the combination index (CI) as a non-constant combination following the Chou-Talalay method [26] whose results are summarized as polygonograms in Fig. 5e. CI results are shown for SCaBER in Fig. 5a to c according to the fraction affected by combined treatment. Strong synergism was
shown for erlotinib equal to or higher than its IC₅₀ value which caused CI values ranging between 0.20 and 0.72 in combination with different concentrations of cisplatin (Fig. 5a). CI values in the range of 0.84–94.22 were calculated at lower concentrations of both drugs reflecting antagonistic effects. Combined erlotinib and gemcitabine treatment revealed an unambiguous synergism for all tested combinations (CI range: 0.03–0.39). Combinations of gefitinib and cisplatin showed synergistic effects for almost all applied doses (CI range: 0.077–0.784). A dose-dependent range of CI was calculated while using combined gefitinib-gemcitabine application reflecting either synergism at high concentrations (CI range 0.02–0.15) or both synergism and antagonism at low concentrations (CI range 0.03–3.60) (Fig. 5b). Furthermore, combination of the two chemotherapeutics cisplatin and gemcitabine achieved the expected strong synergism (Fig. 5c) which is in line with previous reports [27]. Combined TKI treatment also improved efficacy with strong synergism for almost all applied dose ranges following a clear dose-dependent effect.

Analyzing the response patterns of the EGFR signaling cascade upon combined treatment of SCaBER, reduced activity for the EGFR-ERK axis was observed only for erlotinib–cisplatin combinations associated with synergistic CI values (Fig. 5f–g). In contrast, combined erlotinib–cisplatin treatment mediating antagonistic effects correlated with increased ERK activation compared to the DMSO control. Cisplatin alone was also associated with p-ERK upregulation. Interestingly, there was a switch from
p-ERK to p-AKT activation when comparing combined erlotinib-cisplatin treatment depending on synergistic/antagonistic doses. Overall, gemcitabine treatment (alone and in combination) was associated with reduced EGFR and AKT activation, whereas phosphorylation of the downstream kinase ERK was not clearly blocked.

Considering the transcriptional regulation of EGFR pathway members (Fig. 5h–l and Supplementary Fig. 6), we confirmed the downregulation of SOX9 only for drug concentrations and combinations mediating synergisms and exhibiting an inactive EGFR-ERK axis, i.e., erlotinib (FC: 0.12) and erlotinib-cisplatin (FC: 0.11). Consistently concentrations/combinations associated with synergistic CI values caused slight or strong re-expression of ERBB4. Interestingly, the combined erlotinib-gemcitabine treatment also showed ERBB4 upregulation (Fig. 5i). However, gemcitabine treatment was associated with the upregulation of all measured ERBB ligands (AREG, EREG, HB-EGF) as well as SOX9 suggesting an interfering impact on the EGFR pathway.

**Proof-of-principle: Impact of anti-EGFR based combined treatment on primary SCC-cells ex vivo**

Primary cells (p-SCC) derived from pure SCC tissue were established as a cell culture ex vivo model. The tissue of origin showed pure squamous differentiation (Fig. 6a, a + b) with abundant KRT5/6 staining (Fig. 6a, c + d). Strong EGFR expression (score 3) was observed in 20% of SCC cells with an overall heterogeneous staining pattern (e + f). Derived p-SCC cells were cultivated under low oxygen conditions (3% O₂). The cells displayed an epithelial, cobblestone-like morphology (Fig. 6a, g – i). p-SCC cells were characterized and compared with the original tumor tissue by transcriptomic analysis. SCaBER and J82 cells served as squamous and urothelial-like controls, respectively. In Fig. 6b, the 111 most up- and downregulated genes (FC ≥ 500) are shown in a heatmap (for detailed gene list see Supplementary Table 5). We observed a close correlation between the gene expression pattern of p-SCC cells and the tissue of origin. Most of the overexpressed or weakly expressed genes could be confirmed in SCaBER.
cells while the urothelial cell line J82 showed a completely different gene expression pattern. mRNA expression of the two basal-type markers KRT6A and KRT14 as well as EGFR confirmed comparable levels between the original tumor tissue and p-SCC (Fig. 6c). Total EGFR protein was slightly lower expressed in p-SCC cells than in SCaBER,
but a high level of activated EGFR was confirmed for p-SCC cells.

Performing single (Fig. 6e and f) and combined drug treatment (Fig. 6e and f) the pool of heterogeneous p-SCC cells showed intermediate sensitivity to both TKIs ranging between 1.97 µM (gefitinib-IC50) and 2.70 µM (erlotinib-IC50) (Fig. 6d) associated with strong inhibition of p-ERK and p-AKT activation as well as SOX9 expression (FC: 0.17) (Supplementary Fig. 7A and B). Interestingly, ERBBs were not differentially expressed, however, AREG, EREG, and HB-EGF normalized to corresponding DMSO control is shown 24 h after treatment of SCaBER cells with indicated drugs. GAPDH was used for standardization. FC: fold change. Vertical lines: ±SEM of triplicates. Data (western blot and mRNA expression) were confirmed by n = 3 independent experiments.

Discussion

Aberrant activation of ERBB signaling pathways has emerged as an effective therapeutic target in the field of precision medicine [23]. EGFR inhibition by monoclonal antibodies or small molecule TKIs has been approved for the treatment of tumor entities like RAS wild-type colorectal cancers [28], HNSCC [29], and EGFR-mutated NSCLC [16, 30]. In the present study, we provide a rationale for combining EGFR inhibitors with standard chemotherapy as treatment strategy for pure and mixed squamous bladder cancers, characterized by a strong dependency on wild-type EGFR signaling. Functionally, we confirmed a central role of wild-type EGFR in squamous-differentiated bladder cancer cells, as they are vulnerable to perturbances of the ERBB signaling pathway in vitro. SCaBER cells, lacking activating mutations or amplifications of the EGFR gene, were highly sensitive to treatment with both anti-EGFR TKIs erlotinib and gefitinib. The corresponding IC50 value is very close to those reported for EGFR-mutated NSCLC cell lines (example for gefitinib sensitivity: PC-9 (del 746–750) IC50 = 0.0235 µM) [30]. An intermediate sensitivity to anti-EGFR TKIs was confirmed in primary SCC cells whose IC50 range was comparable to that of oropharyngeal squamous cancer cell lines. Bearing in mind that EGFR is a validated target in HNSCC [29], our in vitro data suggest promising efficacy of anti-EGFR TKIs in Sq-BLCA of the urinary bladder as well. This hypothesis fits to our molecular and functional findings of the ERBB pathway. In SCaBER and p-SCC cells, the activity of the EGFR receptor and the downstream kinases ERK/AKT were effectively blocked upon TKI treatment. A feedback loop mechanism upregulating ERBB4 receptors was observed in SCaBER, but feedbacks reinforcing EGFR signaling were not shown, i.e., the target gene SOX9 [25] remained suppressed while EGFR ligands such as HB-EGF were downregulated upon inhibition. A functional knockdown of EGFR by siRNA confirmed strong dependency of SCaBER cells on the ERBB pathway as EGFR loss was associated with reduced cell viability. Hence, squamous-differentiated bladder cancer appears to be oncogenically addicted to EGFR activity and consequently sensitive to both EGFR inhibition and knockdown without any short-term escape mechanisms, thereby suggesting a putative “Achilles heel”.

In contrast, invasive urothelial cancer cells were characterized by poorer sensitivity to treatment with anti-EGFR TKIs (IC50 > 3 µM). EGFR inhibition did not result in a significant inactivation of ERK or AKT in J82 cells. A single activating mutation in ERBB2 (R678Q) may contribute to reduced sensitivity against TKIs by heterodimerization with EGFR. Beyond that, we did not find genetic alterations in EGFR or downstream effectors in J82 cells, which could further mediate an anti-EGFR drug resistance. Interestingly, we observed a short-term feedback response upon erlotinib treatment in J82 cells, i.e., EGFR, ERBB3, and EREG were upregulated. Mutual compensation by other members of the ERBB family has been described as a bypass mechanism to evade ERBB-TKI inhibition, thus the observed feedback may indeed limit the sustained...
inhibition of the ERBB pathway in J82. In particular trans-phosphorylation of ERBB3 mediated by compensatory pathways like the PI(3)K/AKT signaling cascade has been proposed to bypass the impact of ERBB TKIs [31, 32]. In addition, EREG has been shown to induce weaker EGFR dimers but causing sustained EGFR signaling [33]. As a
clinical consequence, ERBB pathway inhibition may have limited overall efficacy in non-squamous urothelial tumor cells relieving the pathway repression which may explain why unevaluated clinical trials failed to demonstrate the clinical significance of EGFR inhibition in bladder cancer so far [34, 35]. This agrees with Eriksson and colleagues who concluded that the application of EGFR/HER2 inhibitors did not adequately consider the molecular heterogeneity of bladder cancers in clinical trials [36].

By combining EGFR inhibitors and cytotoxic chemotherapeutics, we further revealed strong synergistic effects in ScABER cells. Interestingly, combinations of different TKIs, i.e., gefitinib-erlotinib, also improved drug efficiency in both ScABER and p-SCC. As synergisms are thought to be basically a physiochemical mass-action law issue of the drug-receptor interaction, i.e., any reaction is proportional to the concentrations of the reactants [37, 38], synergistic effects may hint at slightly different affinities of both TKIs to EGFR. Beyond that, lack of specificity is assumed for diverse TKIs including erlotinib and gefitinib [39], suggesting putative further targets of strong homology such as ERBB2/HER2 which might be especially noticeable in the pool of p-SCC cells derived from a tumor with heterogeneous EGFR expression. Non-EGFR specific effects might be also responsible for EGFR and ERBB3 upregulation upon erlotinib treatment in J82 cells as we could not confirm similar responses after a functional EGFR knockdown.

Nevertheless, it should be noted that not every combination is necessarily useful. Combined treatment also caused a concentration-dependent antagonism albeit to a lesser extent. Although the mass-action law seems critical, drug potency in pharmacological models is more complex [40] and antagonisms of combined TKI-chemotherapeutic treatment could be discussed in a mechanistically context as well. It has been shown that the application of gefitinib and cisplatin displayed a dose-dependent antagonism in EGFR wild-type and EGFR mutant NSCLC cell lines, unveiling an interference of cisplatin cell entry [30] at a concentration range of gefitinib between 0.001–0.3 μM. Tsai et al. concluded that this antagonism might partly explain why randomized trials including standard chemotherapeutics to NSCLC failed to show benefits for this combined regimen [41]. It has been further proven that both the order and the timing of the application of an EGFR inhibitor and a chemotherapeutic agent could be important to achieve clinical benefits for the patients. Cisplatin followed by afatinib exposure caused more cytotoxic effects than the reverse order or simultaneous application [42]. Considering the order of treatment, mechanisms impairing the efficacies of EGFR inhibitors and cisplatin have been reported in both directions [43]. Ahsan et al. have demonstrated antagonistic effects due to an inhibitory impact of EGFR treatment on cisplatin-induced EGFR phosphorylation [44]. In addition, Benhar et al. demonstrated ERK activation induced by cisplatin [45] which fits to the here observed signaling response patterns. It has been further shown that gemcitabine induces ligands of the EGFR pathway such as AREG [46] which was similar to our findings associated with activated EGFR signaling. Thus, attenuating a general gemcitabine-driven activation of the EGFR pathway by simultaneous application of TKIs may support our observed synergistic impact of combined erlotinib-gemcitabine treatment. In light of such interferences with the EGFR pathway clinical usability of TKI-chemotherapy combinations remains questionable from mechanistically aspects as a clear EGFR pathway inhibition was not detectable. However, combined erlotinib-cisplatin treatment reached EGFR signaling inhibition results equal to those of an individual use of erlotinib (without evidence of compensatory effects), but with an additional cytotoxic impact of cisplatin. Since a combination of targeted therapeutics with common treatment strategies is known to improve clinical outcomes of NSCLC patients [47, 48] this option may be an example of how to translate such in vitro data into a clinical study as previously demonstrated for HNSCC [49].

In summary, our study reveals that Sq-BLCA is highly sensitive to inhibition of the wild-type EGFR signaling pathway lacking known intrinsic mechanisms of ERBB-family TKI resistance. Our in vitro data give further evidence thatSq-BLCA patients may benefit from combined treatment with anti-EGFR TKIs and chemotherapeutics, in particular by dual targeting of the EGFR signaling pathway from different sites as previously assessed in a clinical trial [50]. The order and timing of the combinatorial treatment
strategy should be considered for future study designs, and histological and molecular testing of bladder cancer prior to treatment might be the key to improve therapeutic management for (Sq-BLCA) patients.

**Materials and methods**

**Patient samples**

A non-schistosomal squamous bladder cancer cohort ($n = 75$ different pure SCCs, $n = 50$ different urothelial carcinomas with substantial partial (>50%) squamous differentiation) of formalin-fixed paraffin-embedded (FFPE) surgical specimens from collaborating Institutes of Pathology in Germany and the German Study Group of Bladder Cancers (DFBK e.V.) was used (see Table 1). Tissue microarray construction (TMA) has been described previously [51]. For the comparison of EGFR and ERBB2/HER2 protein expression additional TMAs of a MIBC cohort without squamous differentiation ($n = 63$, pure urothelial MIBC) were used (Supplementary Table 1). Due to the limited availability of material, experimental or clinical data, and case numbers vary for different methods as indicated. Clinical data were obtained by the records of the Departments of Urology and the local ethics committee approved the retrospective, pseudonymized study of archival tissues (RWTH EK 009/12). Tumor tissue of an individual diagnosed with a pure SCC was obtained from the RWTH centralized biomaterial bank (RWTH cBMB) for SCC-tumor cell isolation. The patient gave written consent and experiments were in accordance with the regulations of the biomaterial bank and the Institutional Review Board (IRB)-approved protocols of the Medical Faculty (RWTH EK 206/09, study number 199).

**SCC-tumor cell isolation method and cell culture**

Isolation and culturing of primary cells (p-SCC) were performed as described previously for BCSCs [52]. For details of primary cell culture and used cell lines see Supplementary Information. If not otherwise stated all further experiments with the human cells were independently performed at least three times.

**Anti-EGFR and anti-ERBB2/HER2 immunohistochemistry**

Immunohistochemical staining of 3 µm TMA sections with diagnostically approved anti-EGFR (Clone E30, monoclonal mouse, M7239, DAKO, Hamburg, Germany, 1:10) or anti-ERBB2/HER2 antibodies (c-erbB-2, polyclonal rabbit, A0485, DAKO, 1:300) was performed on an autostainer 360 (Thermo Fisher Scientific, Waltham, USA) as previously specified [53]. For modifications see Supplementary Information.

**DNA extraction and Sanger sequencing**

DNA extraction of FFPE tissue samples ($n = 69$ samples) was performed using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. PCR-amplification and Sanger sequencing was done as previously described [54]. For integrative visualization of sequencing data the cBio Cancer Genomics Portal [55] based OncoPrint tool was used [56]. For detailed gene, exon, and primer information see Supplementary Information and Supplementary Table 6.

**Fluorescence in situ hybridization (FISH)**

FISH was performed as reported [54] with slight modifications stated in the Supplementary Information.

**RNA extraction and reverse transcription PCR**

Total RNA was extracted from cultured cells using TRIzol™ reagent (Thermo Fisher Scientific) or using the Nucleospin RNA Plus Kit (Macherey-Nagel, 740984.50) according to the manufacturer’s instructions as indicated. 1 µg of RNA was used for cDNA reverse transcription by Promega Kit A3500 according to the manufacturer’s instructions (Promega, Mannheim, Germany).

**Semi-quantitative real-time PCR**

cDNAs were amplified by real-time PCR using SYBR-Green PCR mix (Bio-Rad Laboratories, Munich, Germany) in an iCycler IQ5 (Bio-Rad Laboratories) as previously described [57]. All primer sequences are listed in Supplementary Table 7. Gene expression was quantified by using the comparative $2^{-\Delta\Delta CT}$ method calculating relative expression values and GAPDH was used for standardization. If the comparison to a reference sample was not applicable, the gene expression was calculated as % expression of the measured GAPDH expression ($2^{-\Delta CT}$) according to Schmittger and Livak [58].

**Western blot**

Western blot analysis was performed as recently described [57] with slight modifications (see Supplementary Information).

**Single and combined drug response assays and pathway analyses**

Dose response curves were performed applying the tyrosine-kinase inhibitors erlotinib (LC Laboratories, 

SPRINGER NATURE
Woburn, MA) and gefitinib (Selleckchem, München, Germany) and the chemotherapeutics gemcitabine and cisplatin (obtained ready to-use from the in-house pharmacy of the RWTH Aachen University Hospital). Cell viability was determined by adding XTT (Roche Diagnostics, Penzberg, Germany) according to the manufacturer’s instructions. For details see Supplementary information.

ERBB pathway stimulation and inhibition

For stimulation with recombinant EGF (10 ng/ml) (GIBCO, Thermo Scientific, MA, USA), and/or erlotinib inhibition (conc. as indicated) up to 24 h, SCaBER, J82, and HT1376 cells were cultured in serum-free media, containing human transferrin and 1% DMSO (Sigma-Aldrich). For p-SCC cells standard conditions (see Supplementary Information) were used. Cellular proteins were extracted in RIPA lysis buffer containing phosphatase inhibitors and quantified using the Pierce™ BCA protein assay (Thermo Scientific, MA, USA). RNA was extracted using the Nucleospin RNA Plus Kit.

RNA interference of EGFR

Cells were transfected with siTran 1.0 siRNA transfection reagent (Origene, Cat. No. TT300002) applying a siRNA directed against EGFR (Origene) according to the manufacturer’s instructions. For details see Supplementary Information.

Cell growth assay

SCaBER cells were seeded 48 h after transfection into 6-well plates (2 × 10^4 cells/well). Twenty-four hours later cells were retreated with siRNA. Cell numbers were determined every 24 h, using Casy®-1 cell counter (OLS Bio, Bremen, Germany).

Apoptosis assay

The Apo-One® Homogeneous Caspase-3/7 Assay (Promega) was used to detect the activity of effector caspases 3 and 7 as previously described [57].

Microarray analysis

Transcriptomic profiling was performed by the IZKF (Interdisciplinary Centre for Clinical Research Aachen) Chip-Facility using the Clariom D gene array (Affymetrix, Santa Clara, CA). For details see Supplementary Information. The microarray data were uploaded to the National Center for Biotechnology Information Gene Expression Omnibus (GSE146975; reviewer access: kxqbicmorfejnvw).

TCGA data acquisition

Public BLCA data sets from the Cancer Genome Atlas (TCGA) [59] network were classified and analyzed as described [22].

Statistics

Statistical analyses were performed using SPSS 25.0 (SPSS, Chicago, IL, USA) and GraphPad Prism 5.0. Differences were considered statistically significant if the two-sided p-values were equal or below 5% (≤0.05). The non-parametric Mann–Whitney U-test was used to compare two groups. Results of single and combination drug assays were used to calculate the Combination Index (CI) with Compusyn (version 1.0) [26, 37].

Acknowledgements The authors appreciate the contributions of all pathologists and urologists sending cases for study material, the German Study Group of Bladder Cancers (DFBK e.V.), as well as the excellent technical support of Uschi Schneider, Patrick Kühle and Anja Steinle. We thank Timon Heide for his great support in analyzing TCGA data sets and are grateful for the publicly available TCGA research Network data sets (http://cancergenome.nih.gov). We further thank Dr. Kathrin Schechenbach (Düsseldorf University Hospital, Germany), Prof. Wolfgang Schulz (Düsseldorf University Hospital, Germany) and Dr. Alexander Buchner (LMU München, Germany) for providing cell lines. We also thank Pia Dinger and Franziska Lammert for proofreading the manuscript. Furthermore, we thank Dr. Olbrich for supporting our study. This project was partly funded by START-funds of the Medical Faculty of the RWTH Aachen University (NTG grant number: 42/13). Open Access funding enabled and organized by Projekt DEAL.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70:106–19.
3. Minato A, Noguchi H, Tomisaki I, Fukuda A, Kubo T, Nakayama T, et al. Clinical significance of squamous differentiation in urothelial carcinoma of the bladder. Cancer Control. 2018;25:1073274818800269.
4. Minato A, Fujimoto N, Kubo T. Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder. Clin Genitourin Cancer. 2017;15:e1063–7.
5. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to front-line chemotherapy. Cancer Cell. 2014;25:152–65.
6. Robertson AG, Kim J, Al-Ahmadi H, Bellmunt J, Guo G, Cermiak AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cancer Cell. 2017;171:540–56. e25.
7. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2019; pii: S0302-2838(19)30695-5.
8. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72:544–54. e3.
9. Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chaumeautblanc E, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6:24ra91.
10. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13:663–73.
11. Casalini P, Iorio MV, Galmozzi E, Ménard S. Role of HER receptors family in development and differentiation. J Cell Physiol. 2004;200:343–50.
12. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21:177–84.
13. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2:451–61.
14. O-Chaoenrat P, Rhys-Evans P, Eccles S. Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int J Cancer. 2000;88:759–64.
15. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.
16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.
17. Chow NH, Liu HS, Yang HB, Chan SH, Su IJ. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. Immunohistochemical study Virchows Arch 1997;430:461–6.
18. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 2001;7:1957–62.
19. Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO. Heparin-binding epithelial growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007;109:2016–24.
20. Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
21. Moosoa BA, Vinalli RL, Mudryj M, Yap SA, de Vere White RW, Ghosh PM. The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence. J Urol. 2015;193:19–29.
22. Baldaia PH, Maurer A, Heide T, Rose M, Stoehr R, Hartmann A, et al. Fibroblast growth factor receptor (FGFRI) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup. Oncotarget. 2016;7:71429–39.
23. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12:553–63.
24. Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, et al. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors. 2012;30:107–16.
25. Ling S, Chang X, Schultz L, Lee TK, Chaux A, Marchiònni L, et al. An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res. 2011;71:3812–21.
26. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.
27. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuijer CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521–30.
28. Liévre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–5.
29. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010;16:2489–95.
30. Tsai CM, Chen JT, Stewart DJ, Chiu CH, Lai CL, Hsiao SY, et al. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? J Thorac Oncol. 2011;6:559–68.
31. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–41.
32. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395–402.
33. Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell. 2017;171:683–95. e18.
34. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 2010;106:349–54.
35. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105:317–21.
36. Eriksson P, Sjödahl G, Chebil G, Liedberg F, Höglund M, HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts. Oncotarget. 2017;8:48905–14.
37. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm Rev. 2006;58:621–81.
38. Ferrer RE, Aronson JK, Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. Br J Clin Pharmacol. 2016;81:52–5.
39. Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol. 2010;249:132–9.

40. Kenakin T. The mass action equation in pharmacology. Br J Clin Pharmacol. 2016;81:41–51.

41. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5:1706–13.

42. Longton E, Schmit K, Fransolet M, Clement F, Michiels C. Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma. Front Oncol. 2018;8:432.

43. Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, et al. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res. 2008;14:6867–76.

44. Alshb A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, et al. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res. 2010;70:2862–9.

45. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGFr receptor. Oncogene. 2002;21:8723–31.

46. Miyahayashi K, Iijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res. 2013;73:2221–34.

47. Herbst RS, O’Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol. 2007;25:4743–50.

48. Yan X, Wang H, Li P, Zhang G, Zhang M, Yang J, et al. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Lung Cancer. 2019;128:6–12.

49. Wirth LJ, Dakhl S, Korke G, Axelrod R, Adkins D, Pant S, et al. PARTNER: an open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016;61:31–40.

50. Weckhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotheraphy-refractory, advanced colorectal cancer. J Clin Oncol. 2012;30:1505–12.

51. Gaisa NT, Braunschweig T, Reimer N, Bornemann J, Elte E, Siegert S, et al. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch. 2011;458:301–12.

52. Metzger E, Stepputtis SS, Stretz J, Preca BT, Urban S, Willmann D, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 2017;77:5900–12.

53. Rose M, Gaisa NT. Immunohistochemical analysis of urothelial carcinoma tissues for proliferation and differentiation markers. Methods Mol Biol. 2018;1655:43–52.

54. Gaisa NT, Graham TA, McDonald SA, Poulson R, Heidenreich A, Jakse G, et al. Clonal architecture of human prostatic epithelium in benign and malignant conditions. J Pathol. 2011;225:172–80.

55. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.

56. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:p1.

57. Rose M, Kloten V, Noetzel E, Gola L, Ehling J, Heide T, et al. ITIH5 mediates epigenetic reprogramming of breast cancer cells. Mol Cancer. 2017;16:44.

58. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.

59. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.